DARPP-32 and t-DARPP promote non-small cell lung cancer growth through regulation of IKKα-dependent cell migration.
Sk Kayum AlamMatteo AstonePing LiuStephanie R HallAbbygail M CoyleErin N DankertDane K HoffmanRui KuangRui KuangAnja C RodenAaron S MansfieldLuke H HoeppnerPublished in: Communications biology (2018)
Lung cancer is the leading cause of cancer-related death worldwide. Here we demonstrate that elevated expression of dopamine and cyclic adenosine monophosphate-regulated phosphoprotein, Mr 32000 (DARPP-32) and its truncated splice variant t-DARPP promote lung tumor growth, while abrogation of DARPP-32 expression in human non-small cell lung cancer (NSCLC) cells reduces tumor growth in orthotopic mouse models. We observe a novel physical interaction between DARPP-32 and inhibitory kappa B kinase-α (IKKα) that promotes NSCLC cell migration through non-canonical nuclear factor kappa-light-chain-enhancer of activated B cells 2 (NF-κB2) signaling. Bioinformatics analysis of 513 lung adenocarcinoma patients reveals elevated t-DARPP isoform expression is associated with poor overall survival. Histopathological investigation of 62 human lung adenocarcinoma tissues also shows that t-DARPP expression is elevated with increasing tumor (T) stage. Our data suggest that DARPP-32 isoforms serve as a negative prognostic marker associated with increasing stages of NSCLC and may represent a novel therapeutic target.
Keyphrases
- nuclear factor
- cell migration
- poor prognosis
- small cell lung cancer
- toll like receptor
- endothelial cells
- binding protein
- advanced non small cell lung cancer
- gene expression
- induced apoptosis
- ejection fraction
- transcription factor
- oxidative stress
- physical activity
- mental health
- inflammatory response
- induced pluripotent stem cells
- metabolic syndrome
- patient reported outcomes
- computed tomography
- artificial intelligence
- pi k akt